Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18967259 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | December 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18807825 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18720291 | IL-4 DERIVED PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | June 2024 | April 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18628440 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18444463 | COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOF | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18221206 | SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF | July 2023 | October 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18341404 | METHOD OF REDUCING GLUCOSE INTOLERANCE OR INSULIN RESISTANCE IN A PATIENT IN NEED THEREOF | June 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
| 18331197 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | June 2023 | April 2025 | Allow | 22 | 2 | 1 | No | No |
| 18331318 | Lyophilized Formulation | June 2023 | April 2024 | Allow | 10 | 1 | 1 | No | No |
| 18199817 | GATA3 INHIBITORS FOR TREATING INSULIN RESISTANCE | May 2023 | June 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18318492 | METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | May 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18196813 | PREPARATION COMPRISING EXANATIDE FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT | May 2023 | June 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18136236 | METHOD OF DELIVERING GONADOTROPIN RELEASING HORMONE OR AN ANALOGUE THEREOF INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | April 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18181852 | NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | March 2023 | February 2025 | Allow | 23 | 1 | 0 | No | No |
| 18087273 | SHORT CHAIN CERAMIDE-BASED LIPIDS AND USES THEREOF | December 2022 | April 2025 | Allow | 28 | 1 | 0 | No | No |
| 18087345 | ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT | December 2022 | April 2025 | Allow | 28 | 1 | 0 | No | No |
| 18077742 | USE OF ULTRARAPID ACTING INSULIN | December 2022 | February 2025 | Allow | 27 | 1 | 0 | No | No |
| 18061182 | FIBROBLAST GROWTH FACTOR 1 (FGF1) MUTANT PROTEINS THAT SELECTIVELY ACTIVATE FGFR1B TO REDUCE BLOOD GLUCOSE | December 2022 | March 2025 | Abandon | 27 | 1 | 0 | No | No |
| 17997363 | Treating Cancer with a Conjugate Comprising an IL-2 Moiety | October 2022 | May 2025 | Allow | 31 | 1 | 1 | No | No |
| 18049445 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION | October 2022 | March 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17929209 | Targeting gamma-delta T Cells in Obesity and Cachexia | September 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17895638 | INSULIN-TRANSFERRIN FUSION PROTEIN AND ITS PRODRUG, PROINSULIN-TRANSFERRIN, FOR OVERCOMING INSULIN RESISTANCE | August 2022 | April 2025 | Allow | 32 | 2 | 0 | No | No |
| 17869948 | METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASE | July 2022 | April 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17813383 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DIABETES AND RELATED DISORDERS | July 2022 | November 2024 | Allow | 28 | 1 | 0 | No | No |
| 17863322 | METHODS FOR DELIVERING ETANERCEPT PREPARATIONS INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17836644 | ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF | June 2022 | December 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17836707 | ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF | June 2022 | January 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 17747723 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE | May 2022 | January 2025 | Allow | 32 | 1 | 0 | No | No |
| 17741126 | Long-Acting Therapeutic Fusion Proteins | May 2022 | March 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17724406 | BIOMARKERS OF FAST PROGRESSION OF CHRONIC KIDNEY DISEASE | April 2022 | September 2024 | Allow | 29 | 0 | 1 | No | No |
| 17721112 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY | April 2022 | March 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17695343 | PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN | March 2022 | March 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17692238 | INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONS | March 2022 | November 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17667223 | A METHOD FOR TREATING DIABETES | February 2022 | November 2024 | Allow | 34 | 2 | 1 | No | No |
| 17588377 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION | January 2022 | January 2025 | Allow | 36 | 1 | 0 | No | No |
| 17586872 | Methods of Treatment Using G-CSF Protein Complex | January 2022 | September 2024 | Allow | 31 | 1 | 0 | No | No |
| 17562435 | RAPID-ACTING INSULIN ANALOGUES OF ENHANCED STABILITY | December 2021 | January 2025 | Allow | 37 | 1 | 0 | No | No |
| 17549770 | PHARMACEUTICAL COMPOSITION COMPRISING FRATAXIN FUSION PROTEIN AND METHODS OF USE THEREOF | December 2021 | April 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17534270 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY | November 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17534291 | METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIES | November 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17611478 | FORMULATIONS OF TERLIPRESSIN | November 2021 | September 2024 | Allow | 34 | 1 | 0 | No | No |
| 17519305 | ACTRIIB LIGAND TRAP COMPOSITIONS AND USES THEREOF | November 2021 | August 2024 | Allow | 34 | 2 | 1 | No | No |
| 17507441 | STEM CELL RICH PLASMA COMPOSITIONS AND USES THEREOF FOR TREATING AGING SUBJECTS | October 2021 | September 2024 | Allow | 35 | 1 | 1 | No | No |
| 17499296 | Method and Compounds for Treating Diabetes and Associated Metabolic Diseases | October 2021 | September 2024 | Allow | 35 | 5 | 1 | Yes | No |
| 17443737 | METHOD FOR SCREENING OF UNPLEASANT ODOR MASKING AGENTS | July 2021 | December 2024 | Allow | 40 | 1 | 0 | No | No |
| 17378184 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC HEART DISEASE | July 2021 | February 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17332578 | NUCLEIC ACID MOLECULES ENCODING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | May 2021 | August 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17327498 | GLUCOSE RESPONSIVE INSULINS | May 2021 | September 2024 | Allow | 40 | 2 | 1 | No | No |
| 17320118 | ENGINEERED CD25 POLYPEPTIDES AND USES THEREOF | May 2021 | June 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17292701 | COMBINATION THERAPIES FOR MULTIPLE MYELOMA | May 2021 | March 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17315168 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | May 2021 | January 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17289898 | Combination Therapy Method of Treating Myeloproliferative Neoplasms with a Diphtheria Toxin-Human Interleukin-3 Conjugate in Combination with Other Agents | April 2021 | March 2025 | Allow | 47 | 1 | 1 | No | No |
| 17237650 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | April 2021 | August 2023 | Allow | 27 | 3 | 0 | No | No |
| 17286445 | SPHINGOSINE KINASE 1 AND FUSION PROTEIN COMPRISING THE SAME AND USE THEREOF | April 2021 | December 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17224068 | LYOPHILIZED MESENCHYMAL STEM CELL DERIVED SECRETOME AND USES THEREOF | April 2021 | August 2024 | Allow | 41 | 2 | 1 | No | No |
| 17151045 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | January 2021 | March 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17256326 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | December 2020 | November 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17254004 | NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF | December 2020 | February 2025 | Allow | 50 | 1 | 1 | No | No |
| 17118915 | METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS | December 2020 | April 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17251061 | METHOD FOR MEDIATING TARGETED DELIVERY OF A COMPOSITION TO THE BRAIN OF A SUBJECT IN NEED THEREOF | December 2020 | August 2024 | Allow | 44 | 1 | 1 | No | No |
| 16971645 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | August 2020 | August 2024 | Allow | 47 | 4 | 0 | Yes | No |
| 16646112 | Adaptation of Hollow-Fiber-Based Cell Culture Technology for the Manufacturing of (1) Neo-Islets, Employed for the Treatment of Type 1 and Type 2 Diabetes Mellitus, and (2) the Generation of Exosomes from Various Cell Types, Used in the Treatment of Different Organ Injuries and Diseases | March 2020 | December 2024 | Allow | 57 | 3 | 1 | No | No |
| 16241932 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | January 2019 | March 2020 | Allow | 15 | 1 | 0 | No | No |
| 16107834 | PRESERVATIVE FREE INSULIN FORMULATIONS | August 2018 | April 2020 | Allow | 20 | 1 | 0 | No | No |
| 15846485 | INSULIN-INCRETIN CONJUGATES | December 2017 | February 2020 | Allow | 26 | 1 | 1 | No | No |
| 15670200 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | August 2017 | September 2018 | Allow | 13 | 1 | 0 | No | No |
| 15538031 | ALPHA-CELL RE-GENERATION COMBINED WITH CONVERSION TO BETA CELLS | June 2017 | November 2019 | Allow | 29 | 4 | 0 | Yes | No |
| 15528172 | PEPTIDES FOR USE IN TREATMENT AND DIAGNOSIS OF TYPE 1 DIABETES | May 2017 | June 2019 | Allow | 25 | 1 | 1 | Yes | No |
| 15484399 | METHODS OF TREATING AN OVERWEIGHT SUBJECT | April 2017 | April 2019 | Allow | 25 | 2 | 0 | No | No |
| 15421473 | ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES | February 2017 | June 2019 | Allow | 29 | 2 | 1 | Yes | No |
| 15320827 | PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF OREXIN-1 RECEPTOR OX1R FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | December 2016 | August 2018 | Allow | 20 | 2 | 0 | Yes | No |
| 15286871 | INSULIN CONJUGATE USING AN IMMUNOGLOBULIN FRAGMENT | October 2016 | January 2018 | Allow | 16 | 1 | 0 | No | No |
| 15117985 | ANTI-PCSK9-GLP-1 FUSIONS AND METHODS FOR USE | August 2016 | April 2018 | Allow | 20 | 1 | 0 | No | No |
| 15102340 | LIPIDATED INCRETIN RECEPTOR LIGAND HUMAN IMMUNOGLOBULIN FC-REGION FUSION POLYPEPTIDES | June 2016 | July 2018 | Allow | 25 | 1 | 1 | No | No |
| 14879428 | Stable GLP-1 Based GLP-1/Glucagon Receptor Co-Agonists | October 2015 | January 2018 | Allow | 27 | 2 | 1 | No | No |
| 14847646 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | September 2015 | May 2017 | Allow | 20 | 2 | 1 | Yes | No |
| 14765931 | A METHOD OF TREATING OBESITY IN A COMPANION ANIMAL COMPRISING ADMINISTERING A MODIFIED CANINE LEPTIN POLYPEPTIDE | August 2015 | February 2018 | Allow | 31 | 2 | 1 | No | No |
| 14808668 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | July 2015 | April 2017 | Allow | 21 | 1 | 1 | Yes | No |
| 14762712 | N-TERMINAL TRUNCATED INSULIN ANALOGUES | July 2015 | March 2017 | Allow | 20 | 1 | 1 | No | No |
| 14637570 | PHARMACEUTICAL COMPOSITION FOR TRANSMUCOSAL DELIVERY AND METHODS FOR TREATING DIABETES IN A SUBJECT IN NEED THEREOF | March 2015 | October 2019 | Allow | 55 | 5 | 1 | Yes | No |
| 14573495 | METHODS OF TREATING AN OVERWEIGHT SUBJECT | December 2014 | January 2017 | Allow | 25 | 1 | 1 | No | No |
| 14554714 | A METHOD FOR TREATMENT OF DIABETES BY A SMALL MOLECULE INHIBITOR FOR GRK5 | November 2014 | May 2016 | Allow | 18 | 1 | 1 | No | No |
| 14524825 | METHODS AND COMPOSITIONS FOR PROMOTING ORGAN GROWTH AND DEVELOPMENT | October 2014 | August 2016 | Allow | 22 | 2 | 0 | No | No |
| 14471258 | Insulin derivatives Containing Additional Disulfide bonds | August 2014 | September 2016 | Allow | 25 | 2 | 1 | Yes | No |
| 14462459 | METHODS FOR THE TREATMENT OF METABOLIC DISORDERS BY A SELECTIVE SMALL MOLECULE AUTOTAXIN INHIBITOR | August 2014 | January 2015 | Allow | 5 | 1 | 0 | Yes | No |
| 14363328 | HUMAN INSULIN ANALOGUE AND ACYLATED DERIVATIVE THEREOF | June 2014 | June 2016 | Allow | 24 | 1 | 1 | Yes | No |
| 14361017 | ANTI-GLUCAGON ANTIBODIES AND USES THEREOF | May 2014 | June 2016 | Allow | 24 | 1 | 1 | No | No |
| 14276104 | METHOD FOR TREATING A NEUROLOGICAL DISORDER ASSOCIATED WITH HYPOXIA USING A SMALL MOLECULE MACROPHAGE MIF INHIBITOR | May 2014 | June 2016 | Allow | 25 | 2 | 1 | Yes | No |
| 14127469 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | March 2014 | December 2015 | Allow | 23 | 1 | 1 | Yes | No |
| 14219743 | Methods and Compositions for Promoting Organ Development | March 2014 | March 2016 | Allow | 24 | 2 | 1 | Yes | No |
| 14195262 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | March 2014 | February 2016 | Allow | 24 | 1 | 1 | No | No |
| 14172680 | SELECTIVE GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | February 2014 | May 2018 | Allow | 52 | 6 | 1 | Yes | No |
| 14153994 | A METHOD OF TREATING A PATIENT DETERMINED TO BE AT RISK OF DEVELOPING OCCULT PANCREATIC BETA-CELL DYSFUNCTION | January 2014 | October 2017 | Allow | 45 | 4 | 1 | Yes | No |
| 14154074 | METHOD OF DETECTION AND TREATMENT OF CLINICALLY SIGNIFICANT POST-PRANDIAL HYPERGLYCEMIA IN NORMOGLYCEMIC PATIENTS | January 2014 | September 2018 | Allow | 56 | 5 | 1 | No | No |
| 14103359 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | December 2013 | January 2017 | Allow | 37 | 4 | 0 | No | No |
| 14046620 | INSULIN ANALOGUES CONTAINING PENTA-FLUORO-PHENYLALANINE AT POSITION B24 | October 2013 | July 2015 | Allow | 22 | 1 | 1 | Yes | No |
| 14032848 | A METHOD OF TREATING A DISEASE OR CONDITION CHARACTERISED BY ABERRANT EPITHELIAL CELL PROLIFERATION | September 2013 | September 2014 | Allow | 12 | 2 | 0 | No | No |
| 13996937 | METHODS FOR TREATING METABOLIC DISORDERS AND OBESITY WITH A PEPTIDE COMPRISING THE AMINO ACID SEQUENCE OF SEQ ID NO: 146 | September 2013 | October 2014 | Allow | 16 | 1 | 1 | Yes | No |
| 13973130 | A METHOD OF DOWNSTREAM PROCESSING FOR CONVERSION OF HUMAN INSULIN PRECURSOR MOLECULE INTO A FUNCTIONAL HUMAN INSULIN PROTEIN MOLECULE | August 2013 | December 2015 | Allow | 28 | 3 | 0 | Yes | No |
| 13924823 | METHODS FOR REDUCING THE RISK OF SPONTANEOUS ABORTION IN A HUMAN FEMALE COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF G-CSF | June 2013 | March 2015 | Allow | 21 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRA, GYAN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHANDRA, GYAN works in Art Unit 1674 and has examined 300 patent applications in our dataset. With an allowance rate of 93.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner CHANDRA, GYAN's allowance rate of 93.3% places them in the 80% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHANDRA, GYAN receive 1.80 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHANDRA, GYAN is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +7.8% benefit to allowance rate for applications examined by CHANDRA, GYAN. This interview benefit is in the 39% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 35.4% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 58.5% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 77.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 42.0% are granted (fully or in part). This grant rate is in the 43% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 34.7% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.